This product is for research use only, not for human use. We do not sell to patients.
| Size | Price | Stock |
|---|---|---|
| 2mg | $250 | To Be Confirmed |
| 5mg | $400 | To Be Confirmed |
| 10mg | $700 | To Be Confirmed |
| 25mg | $1250 | To Be Confirmed |
| 50mg | $1850 | To Be Confirmed |
| 100mg | $2950 | To Be Confirmed |
: Cat #: V3737 CAS #: 156177-65-0 Purity ≥ 98%
Description: CEP-1347 (also known as KT7515), a derivative of the natural product K-252a found in broths of Narcodiopsis bacterium, is a novel, potent and mixed lineage kinase inhibitor (mainly JNK) with IC50 of 30 nM on JNK1. It demonstrates neuroprotective properties and has the potential for the treatment of neurodegenerative diseases such as PD. CEP-1347 promotes neuronal survival at dosages that inhibit activation of JNKs in primary embryonic cultures. CEP-1347 is tested in a large-scale phase 2/3 clinical trial in early Parkinson's disease, in which its safety and tolerability, but nevertheless not efficacy, was demonstrated. . In addition, CEP-1347 has been reported as a promising candidate for cancer stem cell-targeting therapy and that further clinical and preclinical studies are warranted to evaluate its efficacy in cancer treatment.
Publications Citing InvivoChem Products
Product Promise
- Physicochemical and Storage Information
- Protocol
- Related Biological Data
- Stock Solution Preparation
- Quality Control Documentation
| Molecular Weight (MW) | C33H33N3O5S2 |
|---|---|
| Molecular Formula | 615.76 |
| CAS No. | 156177-65-0 |
| Storage | -20℃ for 3 years in powder form |
| -80℃ for 2 years in solvent | |
| Solubility In Vitro | DMSO: >10 mM |
| Water: <1mg/mL | |
| Ethanol: <1mg/mL | |
| Synonyms | KT-7515; KT 7515; KT7515; CEP-1347; CEP 1347; CEP1347; 3,9-Bis((ethylthio)methyl)-K-252a; 3,9-Bis(etsm)-K-252a |
| Protocol | In Vitro | In vitro activity: In vitro, CEP-1347 efficiently induced differentiation and inhibited the self-renewal and tumor-initiating capacities of human cancer stem cells from glioblastoma as well as from pancreatic and ovarian cancers at clinically-relevant concentrations, without impairing the viability of normal fibroblasts and neural stem cells. Kinase Assay: CEP-1347 (also known as KT7515), a derivative of the natural product K-252a found in broths of Narcodiopsis bacterium, is a novel and potent JNK inhibitor with IC50 of 30 nM on JNK1. Cell Assay: Knockdown of survivin overexpressed in ovarian Chemoresistance of cancer stem cells (CSCs) resulted in increased sensitivity to paclitaxel. Treatment at clinically relevant concentrations with CEP-1347, a mixed lineage kinase inhibitor with a known safety profile in humans, reduced survivin expression in ovarian CSCs and sensitized them to paclitaxel. |
|---|---|---|
| In Vivo | In vivo, a 10-day systemic administration of CEP-1347 at a dose that was less than 1/10 the mouse equivalent of the dose safely given to humans for 2 years was sufficient to effectively reduce tumor-initiating cancer stem cells within established tumors in mice. Furthermore, the same treatment protocol significantly extended the survival of mice receiving orthotopic implantation of glioma stem cells. Together, the findings suggest that CEP-1347 is a promising candidate for cancer stem cell-targeting therapy and that further clinical and preclinical studies are warranted to evaluate its efficacy in cancer treatment. | |
| Animal model | Mice with an orthotopic brain tumor model |
| Related Biological Data |
|
|---|
This equation is commonly abbreviated as: C1 V1 = C2 V2
- (1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
- (2) Be sure to add the solvent(s) in order.